Back to Search
Start Over
EMA grants priority medicines designation to Vertex and CRISPR's CTX001 for transfusion-dependent beta thalassemia
- Source :
- PharmaBiz. April 28, 2021
- Publication Year :
- 2021
-
Abstract
- Vertex Pharmaceuticals and CRISPR Therapeutics announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.663136829